Hyaluronan or hylans for knee osteoarthritis?
In joints affected by osteoarthritis, the synovial fluid's capacity to lubricate and to absorb shock are typically reduced. These changes are partly due to a reduction in the size and concentration of hyaluronic acid (hyaluronan) molecules naturally present in synovial fluid. A new approach in the management of osteoarthritis of the knee is to inject hyaluronan or derivatives of this molecule (hylans) into the joint. We consider the place of two preparations: [symbol: see text]Hyalgan and Synvisc.
D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
C049816:hylan; D006820:Hyaluronic Acid